This retrospective review reports on the management and outcomes of retinoblastoma in children treated at Children’s Hospital Westmead (CHW), Sydney. Results were compared to those of a previous retrospective review of RB cases presenting between 1974 and 2005 at the same centre, which was published in this journal. A retrospective review of all cases of retinoblastoma presenting to the Children’s Hospital Westmead Medical between 2008 and 2018 was conducted. 67 patients were included in the study with a mean age at presentation of 23.5-months and 9.2-months for unilateral and bilateral disease respectively. All patients in our cohort were offered genetic testing. The rate of germline RB1 mutation in our cohort was 29% for unilateral disease and 86% for bilateral disease. Mean follow-up period was 48 months. Globe salvage rates in patients with bilateral disease was 57%, compared to the previous study which was 47%. The most common treatment-related ocular complication was strabismus. Our cohort had only one patient develop metastatic disease and one patient who presented with trilateral disease, which was a case of delayed presentation and was the only mortality in the study. Morbidity and mortality rates in our cohort are on par with other tertiary centres internationally. There has been a significant improvement in globe salvage rate with our current management protocol. As intra-arterial chemotherapy is implemented into the treatment regime at CHW, these results will provide a benchmark to ensure that the excellent standards of care and outcomes are maintained.
| Published in | International Journal of Ophthalmology & Visual Science (Volume 6, Issue 4) |
| DOI | 10.11648/j.ijovs.20210604.24 |
| Page(s) | 273-280 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Retinoblastoma, Chemotherapy, Enucleation
| [1] | Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. British Journal of Ophthalmology. 2009; 93 (9): 1129-31. |
| [2] | Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68 (4): 820-3. |
| [3] | Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A Human DNA Segment with Properties of the Gene That Predisposes to Retinoblastoma and Osteosarcoma. Nature. 1986; 323 (6089): 643-6. |
| [4] | Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecologic Oncology. 2000; 77 (1): 137-48. |
| [5] | Theriault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol. 2014; 42 (1): 33-52. |
| [6] | Gunduz K, Muftuoglu O, Gunalp I, Unal E, Tacyildiz N. Metastatic retinoblastoma clinical features, treatment, and prognosis. Ophthalmology. 2006; 113 (9): 1558-66. |
| [7] | Fabian ID, Onadim Z, Karaa E, Duncan C, Chowdhury T, Scheimberg I, et al. The management of retinoblastoma. Oncogene. 2018; 37 (12): 1551-60. |
| [8] | Abramson DH. Retinoblastoma: saving life with vision. Annu Rev Med. 2014; 65: 171-84. |
| [9] | Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 1999; 36 (1): 8-18; quiz 35-6. |
| [10] | Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective Ophthalmic Artery Chemotherapy as Primary Treatment for Retinoblastoma (Chemosurgery). Ophthalmology. 2010; 117 (8): 1623-9. |
| [11] | Dimaras H, Kimani K, Dimba EAO, Gronsdahl P, White A, Chan HSL, et al. Retinoblastoma. The Lancet. 2012; 379 (9824): 1436-46. |
| [12] | Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet. 2003; 72 (2): 253-69. |
| [13] | Tomar S, Sethi R, Sundar G, Quah TC, Quah BL, Lai PS. Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling. PLoS One. 2017; 12 (6): e0178776. |
| [14] | Berman EL, Donaldson CE, Giblin M, Martin FJ. Outcomes in retinoblastoma, 1974-2005: the Children's Hospital, Westmead. Clin Exp Ophthalmol. 2007; 35 (1): 5-12. |
| [15] | Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005; 18 (1): 41-53, viii. |
| [16] | Fabian ID, Reddy A, Sagoo MS. Classification and staging of retinoblastoma. Community Eye Health. 2018; 31 (101): 11-3. |
| [17] | Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001; 176 (2): 289-96. |
| [18] | Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013; 346: f2360. |
| [19] | Shields CL, Fulco EM, Arias JD, Alarcon C, Pellegrini M, Rishi P, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2013; 27 (2): 253-64. |
| [20] | Manjandavida FP, Honavar SG, Shields CL, Shields JA. Retinoblastoma: Recent Update and Management Frontiers. Asia Pac J Ophthalmol (Phila). 2013; 2 (6): 351-3. |
| [21] | Shields CL, Lally SE, Leahey AM, Jabbour PM, Caywood EH, Schwendeman R, et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014; 25 (5): 374-85. |
| [22] | Tomar AS, Finger PT, Gallie B, Mallipatna A, Kivela TT, Zhang C, et al. A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma: Part I: Metastasis-Associated Mortality. Ophthalmology. 2020; 127 (12): 1719-32. |
| [23] | Mallipatna AC, Sutherland JE, Gallie BL, Chan H, Heon E. Management and outcome of unilateral retinoblastoma. J AAPOS. 2009; 13 (6): 546-50. |
| [24] | Rojanaporn D, Attaseth T, Dieosuthichat W, Leelawongs K, Pakakasama S, Anurathapan U, et al. Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand. J Ophthalmol. 2020; 2020: 4231841. |
| [25] | Posner M, Jaulim A, Vasalaki M, Rantell K, Sagoo MS, Reddy MA. Lag time for retinoblastoma in the UK revisited: a retrospective analysis. BMJ Open. 2017; 7 (7): e015625. |
| [26] | Tomar AS, Finger PT, Gallie B, Mallipatna A, Kivela TT, Zhang C, et al. A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma: Part II: Treatment Success and Globe Salvage. Ophthalmology. 2020; 127 (12): 1733-46. |
| [27] | Jain M, Rojanaporn D, Chawla B, Sundar G, Gopal L, Khetan V. Retinoblastoma in Asia. Eye (Lond). 2019; 33 (1): 87-96. |
| [28] | Dalvin LA, Kumari M, Essuman VA, Shohelly Shipa S, Ancona-Lezama D, Lucio-Alvarez JA, et al. Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience. Ocul Oncol Pathol. 2019; 5 (2): 139-46. |
| [29] | Shields CL, Alset AE, Say EA, Caywood E, Jabbour P, Shields JA. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus. 2016; 53 (5): 275-84. |
| [30] | Munier FL, Mosimann P, Puccinelli F, Gaillard MC, Stathopoulos C, Houghton S, et al. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment. Br J Ophthalmol. 2017; 101 (8): 1086-93. |
| [31] | de Jong MC, Kors WA, de Graaf P, Castelijns JA, Moll AC, Kivela T. The Incidence of Trilateral Retinoblastoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2015; 160 (6): 1116-26 e5. |
| [32] | Kaliki S, Srinivasan V, Gupta A, Mishra DK, Naik MN. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015; 122 (6): 1165-72. |
| [33] | Rojanaporn D, Boontawon T, Chareonsirisuthigul T, Thanapanpanich O, Attaseth T, Saengwimol D, et al. Spectrum of germline RB1 mutations and clinical manifestations in retinoblastoma patients from Thailand. Mol Vis. 2018; 24: 778-88. |
APA Style
Julia Mary Starte, Amir Taher, Madeleine Powys, Craig Donaldson, Luciano Dalla-Pozza, et al. (2021). Management and Outcomes of Retinoblastoma Cases Presenting to Children’s Hospital Westmead, Sydney Between 2008 and 2018. International Journal of Ophthalmology & Visual Science, 6(4), 273-280. https://doi.org/10.11648/j.ijovs.20210604.24
ACS Style
Julia Mary Starte; Amir Taher; Madeleine Powys; Craig Donaldson; Luciano Dalla-Pozza, et al. Management and Outcomes of Retinoblastoma Cases Presenting to Children’s Hospital Westmead, Sydney Between 2008 and 2018. Int. J. Ophthalmol. Vis. Sci. 2021, 6(4), 273-280. doi: 10.11648/j.ijovs.20210604.24
AMA Style
Julia Mary Starte, Amir Taher, Madeleine Powys, Craig Donaldson, Luciano Dalla-Pozza, et al. Management and Outcomes of Retinoblastoma Cases Presenting to Children’s Hospital Westmead, Sydney Between 2008 and 2018. Int J Ophthalmol Vis Sci. 2021;6(4):273-280. doi: 10.11648/j.ijovs.20210604.24
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijovs.20210604.24,
author = {Julia Mary Starte and Amir Taher and Madeleine Powys and Craig Donaldson and Luciano Dalla-Pozza and Bhavna Padhye and Robyn Jamieson and Michael Murray Jones},
title = {Management and Outcomes of Retinoblastoma Cases Presenting to Children’s Hospital Westmead, Sydney Between 2008 and 2018},
journal = {International Journal of Ophthalmology & Visual Science},
volume = {6},
number = {4},
pages = {273-280},
doi = {10.11648/j.ijovs.20210604.24},
url = {https://doi.org/10.11648/j.ijovs.20210604.24},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20210604.24},
abstract = {This retrospective review reports on the management and outcomes of retinoblastoma in children treated at Children’s Hospital Westmead (CHW), Sydney. Results were compared to those of a previous retrospective review of RB cases presenting between 1974 and 2005 at the same centre, which was published in this journal. A retrospective review of all cases of retinoblastoma presenting to the Children’s Hospital Westmead Medical between 2008 and 2018 was conducted. 67 patients were included in the study with a mean age at presentation of 23.5-months and 9.2-months for unilateral and bilateral disease respectively. All patients in our cohort were offered genetic testing. The rate of germline RB1 mutation in our cohort was 29% for unilateral disease and 86% for bilateral disease. Mean follow-up period was 48 months. Globe salvage rates in patients with bilateral disease was 57%, compared to the previous study which was 47%. The most common treatment-related ocular complication was strabismus. Our cohort had only one patient develop metastatic disease and one patient who presented with trilateral disease, which was a case of delayed presentation and was the only mortality in the study. Morbidity and mortality rates in our cohort are on par with other tertiary centres internationally. There has been a significant improvement in globe salvage rate with our current management protocol. As intra-arterial chemotherapy is implemented into the treatment regime at CHW, these results will provide a benchmark to ensure that the excellent standards of care and outcomes are maintained.},
year = {2021}
}
TY - JOUR T1 - Management and Outcomes of Retinoblastoma Cases Presenting to Children’s Hospital Westmead, Sydney Between 2008 and 2018 AU - Julia Mary Starte AU - Amir Taher AU - Madeleine Powys AU - Craig Donaldson AU - Luciano Dalla-Pozza AU - Bhavna Padhye AU - Robyn Jamieson AU - Michael Murray Jones Y1 - 2021/12/29 PY - 2021 N1 - https://doi.org/10.11648/j.ijovs.20210604.24 DO - 10.11648/j.ijovs.20210604.24 T2 - International Journal of Ophthalmology & Visual Science JF - International Journal of Ophthalmology & Visual Science JO - International Journal of Ophthalmology & Visual Science SP - 273 EP - 280 PB - Science Publishing Group SN - 2637-3858 UR - https://doi.org/10.11648/j.ijovs.20210604.24 AB - This retrospective review reports on the management and outcomes of retinoblastoma in children treated at Children’s Hospital Westmead (CHW), Sydney. Results were compared to those of a previous retrospective review of RB cases presenting between 1974 and 2005 at the same centre, which was published in this journal. A retrospective review of all cases of retinoblastoma presenting to the Children’s Hospital Westmead Medical between 2008 and 2018 was conducted. 67 patients were included in the study with a mean age at presentation of 23.5-months and 9.2-months for unilateral and bilateral disease respectively. All patients in our cohort were offered genetic testing. The rate of germline RB1 mutation in our cohort was 29% for unilateral disease and 86% for bilateral disease. Mean follow-up period was 48 months. Globe salvage rates in patients with bilateral disease was 57%, compared to the previous study which was 47%. The most common treatment-related ocular complication was strabismus. Our cohort had only one patient develop metastatic disease and one patient who presented with trilateral disease, which was a case of delayed presentation and was the only mortality in the study. Morbidity and mortality rates in our cohort are on par with other tertiary centres internationally. There has been a significant improvement in globe salvage rate with our current management protocol. As intra-arterial chemotherapy is implemented into the treatment regime at CHW, these results will provide a benchmark to ensure that the excellent standards of care and outcomes are maintained. VL - 6 IS - 4 ER -
Information
Email: